Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez & Domingo Orozco. (2018) Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec. Current Medical Research and Opinion 34:6, pages 1053-1059.
Read now
Read now
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson & Susanne Ellfors-Zetterlund. (2017) Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Current Medical Research and Opinion 33:4, pages 647-655.
Read now
Read now
James Weatherall, Lisa Bloudek & Sarah Buchs. (2017) Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. Current Medical Research and Opinion 33:2, pages 231-238.
Read now
Read now
Articles from other publishers (25)
Jason E. Black, Stewart B. Harris, Bridget L. Ryan, Guangyong Zou & Alexandria Ratzki-Leewing. (2023) Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US). Diabetes Therapy 14:8, pages 1299-1317.
Crossref
Crossref
G. R. Galstyan. (2023) The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia. Diabetes mellitus 26:1, pages 55-65.
Crossref
Crossref
Mussa H. AlMalki, Hossam Aldesokey, Dania Alkhafaji, Abdulrahman Alsheikh, Uffe Christian Braae, Lars Lang Lehrskov, Waleed Magawry, Moataz Yahia & Ahmed Haroun. (2022) Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia. Advances in Therapy 40:2, pages 568-584.
Crossref
Crossref
Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Crossref
Oleksandr Baran, Deonne Dersch-Mills, Jeffrey A. Bakal, Trudy Huyghebaert, Melanie Hnatiuk & Rhonda L. Roedler. (2022) Clinical Utility of Switching to Insulin Degludec From Other Basal Insulins in Adult Patients With Type 1 or Type 2 Diabetes. Canadian Journal of Diabetes 46:4, pages 381-387.e4.
Crossref
Crossref
Jun Li & Qingzhen He. (2022) Evaluation of Tresiba Combined with Six Ingredient Rehmannia Pill in the Treatment of Type 2 Diabetes. Journal of Healthcare Engineering 2022, pages 1-6.
Crossref
Crossref
Junko Oya, Tomoko Nakagami, Yukiko Hasegawa, Aki Katamine, Yuichiro Kondo & Tetsuya Babazono. (2021) Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes. Journal of Diabetes Investigation 12:11, pages 1983-1991.
Crossref
Crossref
Florentino Carral San Laureano, Mariana Tomé Fernández-Ladreda, Ana Isabel Jiménez Millán, Concepción García Calzado & María del Carmen Ayala Ortega. (2023) Insulin Doses Requirements in Patients with Type 1 Diabetes Using Glargine U300 or Degludec in Routine Clinical Practice. Journal of Investigative Medicine 69:5, pages 983-988.
Crossref
Crossref
Malin Sellbom & Charlotta Nilsson. (2021) Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes. Practical Diabetes 38:2, pages 13-19.
Crossref
Crossref
Gian Paolo Fadini, Carla Giordano, Laura Salvi & Antonio Nicolucci. (2020) Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study. Diabetes Therapy 11:12, pages 2909-2920.
Crossref
Crossref
Gian Paolo Fadini, Michael Feher, Troels Krarup Hansen, Harold W de Valk, Mette Marie Koefoed, Michael Wolden, Esther Zimmermann & Johan Jendle. (2019) Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. The Journal of Clinical Endocrinology & Metabolism 104:12, pages 5977-5990.
Crossref
Crossref
Nandu Thalange, Torben Biester & Thomas Danne. (2019) Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports. Diabetes Therapy 10:4, pages 1219-1237.
Crossref
Crossref
S. T. Knudsen, A. Lapolla, B. Schultes, N. Tentolouris, A.‐M. Catarig, M. L. Wolden & T. Siegmund. (2019)
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (
EU
‐
TREAT
)
. Diabetic Medicine.
Crossref
Crossref
Alice Y. Y. Cheng, Dhiren K. Patel, Timothy S. Reid & Kathleen Wyne. (2019) Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Advances in Therapy 36:5, pages 1018-1030.
Crossref
Crossref
Nikolaos Tentolouris, Søren T. Knudsen, Annunziata Lapolla, Michael Lyng Wolden, Steffen Haldrup & Bernd Schultes. (2019) Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control. Advances in Therapy 36:5, pages 1201-1210.
Crossref
Crossref
Muhammad Ali Karamat, Shujah Dar, Srikanth Bellary & Abd A. Tahrani. (2018) Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project. Diabetes Therapy 9:2, pages 839-849.
Crossref
Crossref
Pratik Choudhary & Stephanie A. Amiel. (2018) Hypoglycaemia in type 1 diabetes: technological treatments, their limitations and the place of psychology. Diabetologia 61:4, pages 761-769.
Crossref
Crossref
Thorsten Siegmund, Nikolaos Tentolouris, Søren T. Knudsen, Annunziata Lapolla, Rudolf Prager, Tra-Mi Phan, Michael L. Wolden & Bernd Schultes. (2018) A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes, Obesity and Metabolism 20:3, pages 689-697.
Crossref
Crossref
M. Rodacki, R.M. Carvalho & L. Zajdenverg. (2017) The potential effect of ultra-long insulin degludec on glycemic variability. Diabetes Research and Clinical Practice 133, pages 92-103.
Crossref
Crossref
Cheli Melzer Cohen, Brian Larsen Thorsted, Michael Lyng Wolden, Gabriel Chodick & Avraham Karasik. (2017) Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study. Diabetes Therapy 8:5, pages 1047-1055.
Crossref
Crossref
Barbara Bohn, Artur Zimmermann, Christian Wagner, Sigrun Merger, Desirée Dunstheimer, Florian Kopp, Katja Gollisch, Volker Zindel & Reinhard W. Holl. (2017) Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry. Diabetes Research and Clinical Practice 129, pages 52-58.
Crossref
Crossref
Daniela Sofra. (2017) Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center. Diabetes Therapy 8:2, pages 377-384.
Crossref
Crossref
Jun Suzuki, Tadashi Yamakawa, Joe Nagakura, Erina Shigematsu, Kazuaki Kadonosono & Yasuo Terauchi. (2016) Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study. Diabetology International 8:1, pages 45-51.
Crossref
Crossref
Kohei Kaku, Michael Lyng Wolden, Jacob Hyllested-Winge & Emil Nørtoft. (2017) Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data. Diabetes Therapy 8:1, pages 189-195.
Crossref
Crossref
S. Heller, C. Mathieu, R. Kapur, M. L. Wolden & B. Zinman. (2016) A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabetic Medicine 33:4, pages 478-487.
Crossref
Crossref